Press release
Endometriosis Pipeline 2024: Detailed Clinical Trials and FDA-Approved Therapies Review by DelveInsight | Organon, Ironwood Pharma, AbbVie/Neurocrine Biosciences, Mitsubishi Tanabe Pharma Corporation
The Endometriosis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
"Endometriosis Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Endometriosis Market.
Some of the key takeaways from the Endometriosis Pipeline Report: https://www.delveinsight.com/sample-request/endometriosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Endometriosis treatment therapies with a considerable amount of success over the years.
• Endometriosis companies working in the treatment market are Nanjing Chia-tai Tianqing Pharmaceutical, Hera Biotech, Inc., Bio Genuine (Shanghai) Biotech Co., Ltd., Sumitomo Pharma Switzerland GmbH, Organon, Ironwood Pharmaceuticals, Mitsubishi Tanabe Pharma Corporation, AbbVie/Neurocrine Biosciences, ObsEva/Kissei Pharmaceuticals, SWK/Enteris BioPharma, Bayer/Hope Medicine, Tiumbio, and others, are developing therapies for the Endometriosis treatment
• Emerging Endometriosis therapies in the different phases of clinical trials are- Elagolix, MetriDx, BG2109, Relugolix Combination Tablet, FOR 6219, IW-3300, MT-2990, ORIAHNN (elagolix/estradiol/norethindrone acetate), Linzagolix (OBE2109), OVAREST (leuprorelin oral), HMI-115, TU2670 (NCE-403), OG-6219, and others are expected to have a significant impact on the Endometriosis market in the coming years.
• In October 2024, Lisata Therapeutics, Inc. (Nasdaq: LSTA), a clinical-stage pharmaceutical company focused on developing innovative treatments for advanced solid tumors and other serious diseases, has announced a sponsored research agreement with the University of Cincinnati. The agreement will explore the use of Lisata's novel cyclic peptide product, certepetide, in combination with bevacizumab (a VEGF inhibitor) in a preclinical animal model for treating endometriosis. While bevacizumab has shown efficacy in treating endometriosis, its high dosage levels can cause systemic side effects, limiting its use in otherwise healthy young women. Lisata will provide funding and certepetide for the research conducted by the University of Cincinnati.
• In March 2024, By the end of this year, Gynica, headquartered in Israel, plans to administer the first dose to a patient in a Phase I trial evaluating its cannabioid-based treatments, IntraVagS301 and IntraVagS302, for endometriosis.
Endometriosis Overview
Endometriosis is a condition where tissue similar to the lining of the uterus (endometrium) grows outside the uterus, often on the ovaries, fallopian tubes, and pelvic tissue. This tissue behaves like the uterine lining, thickening, breaking down, and bleeding with each menstrual cycle, but it has no way to exit the body, leading to inflammation, pain, and sometimes infertility. Common symptoms include pelvic pain, heavy menstrual bleeding, and pain during intercourse or bowel movements. The exact cause is unknown, but factors like genetics, immune system disorders, or hormonal imbalances may contribute. Treatment options include pain management, hormonal therapy, and surgery.
Get a Free Sample PDF Report to know more about Endometriosis Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/endometriosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Emerging Endometriosis Drugs Under Different Phases of Clinical Development Include:
• Elagolix: Nanjing Chia-tai Tianqing Pharmaceutical
• MetriDx: Hera Biotech, Inc.
• BG2109: Bio Genuine (Shanghai) Biotech Co., Ltd.
• Relugolix Combination Tablet: Sumitomo Pharma Switzerland GmbH
• FOR 6219: Organon
• IW-3300: Ironwood Pharmaceuticals
• MT-2990: Mitsubishi Tanabe Pharma Corporation
• ORIAHNN (elagolix/estradiol/norethindrone acetate): AbbVie/Neurocrine Biosciences
• Linzagolix (OBE2109): ObsEva/Kissei Pharmaceuticals
• OVAREST (leuprorelin oral): SWK/Enteris BioPharma
• HMI-115: Bayer/Hope Medicine
• TU2670 (NCE-403): Tiumbio
• OG-6219: Organon
• Quinagolide: Ferring Pharmaceuticals
• Linzagolix: ObsEva
Endometriosis Route of Administration
Endometriosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Inhalation
• Inhalation/Intravenous/Oral
• Intranasal
• Intravenous
• Intravenous/ Subcutaneous
• NA
• Oral
• Oral/intranasal/subcutaneous
• Parenteral
• Subcutaneous
Endometriosis Molecule Type
Endometriosis Products have been categorized under various Molecule types, such as
• Antibody
• Antisense oligonucleotides
• Immunotherapy
• Monoclonal antibody
• Peptides
• Protein
• Recombinant protein
• Small molecule
• Stem Cell
• Vaccine
Endometriosis Pipeline Therapeutics Assessment
• Endometriosis Assessment by Product Type
• Endometriosis By Stage and Product Type
• Endometriosis Assessment by Route of Administration
• Endometriosis By Stage and Route of Administration
• Endometriosis Assessment by Molecule Type
• Endometriosis by Stage and Molecule Type
DelveInsight's Endometriosis Report covers around 20+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration
Further Endometriosis product details are provided in the report. Download the Endometriosis pipeline report to learn more about the emerging Endometriosis therapies
https://www.delveinsight.com/sample-request/endometriosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the key companies in the Endometriosis Therapeutics Market include:
Key companies developing therapies for Endometriosis are - AbbVie, Neurocrine Biosciences, Kissei Pharmaceuticals, SWK, Enteris BioPharma, Bayer, Hope Medicine, Tiumbio, Organon, Ferring Pharmaceuticals, ObsEva SA, Myovant Sciences, Hope Medicine (Nanjing) Co., Ltd, TiumBio Co., Ltd., Mitsubishi Tanabe Pharma, and others.
Endometriosis Pipeline Analysis:
The Endometriosis pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Endometriosis with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Endometriosis Treatment.
• Endometriosis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Endometriosis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Endometriosis market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Endometriosis drugs and therapies
https://www.delveinsight.com/sample-request/endometriosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Endometriosis Pipeline Market Drivers
• The development of drug delivery systems represents a new approach in pain treatment among endometriosis patients, extensive research on Non-steroidal anti-inflammatory drugs are some of the important factors that are fueling the Endometriosis Market.
Endometriosis Pipeline Market Barriers
• However, less robust pipeline, high cost of treatment procedures and other factors are creating obstacles in the Endometriosis Market growth.
Scope of Endometriosis Pipeline Drug Insight
• Coverage: Global
• Key Endometriosis Companies: Nanjing Chia-tai Tianqing Pharmaceutical, Hera Biotech, Inc., Bio Genuine (Shanghai) Biotech Co., Ltd., Sumitomo Pharma Switzerland GmbH, Organon, Ironwood Pharmaceuticals, Mitsubishi Tanabe Pharma Corporation, AbbVie/Neurocrine Biosciences, ObsEva/Kissei Pharmaceuticals, SWK/Enteris BioPharma, Bayer/Hope Medicine, Tiumbio, and others
• Key Endometriosis Therapies: Elagolix, MetriDx, BG2109, Relugolix Combination Tablet, FOR 6219, IW-3300, MT-2990, ORIAHNN (elagolix/estradiol/norethindrone acetate), Linzagolix (OBE2109), OVAREST (leuprorelin oral), HMI-115, TU2670 (NCE-403), OG-6219, and others
• Endometriosis Therapeutic Assessment: Endometriosis current marketed and Endometriosis emerging therapies
• Endometriosis Market Dynamics: Endometriosis market drivers and Endometriosis market barriers
Request for Sample PDF Report for Endometriosis Pipeline Assessment and clinical trials
https://www.delveinsight.com/sample-request/endometriosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Table of Contents
1. Endometriosis Report Introduction
2. Endometriosis Executive Summary
3. Endometriosis Overview
4. Endometriosis- Analytical Perspective In-depth Commercial Assessment
5. Endometriosis Pipeline Therapeutics
6. Endometriosis Late Stage Products (Phase II/III)
7. Endometriosis Mid Stage Products (Phase II)
8. Endometriosis Early Stage Products (Phase I)
9. Endometriosis Preclinical Stage Products
10. Endometriosis Therapeutics Assessment
11. Endometriosis Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Endometriosis Key Companies
14. Endometriosis Key Products
15. Endometriosis Unmet Needs
16 . Endometriosis Market Drivers and Barriers
17. Endometriosis Future Perspectives and Conclusion
18. Endometriosis Analyst Views
19. Appendix
20. About DelveInsight
Related Reports:
Endometriosis Market https://www.delveinsight.com/report-store/endometriosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Endometriosis Market Insights, Epidemiology, and Market Forecast-2034' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),
Latest Reports:
• Transdermal Drug Delivery Devices: https://www.delveinsight.com/report-store/transdermal-drug-delivery-devices-market
• Infusion Pumps Market: https://www.delveinsight.com/report-store/infusion-pumps-market
• Acute Radiation Syndrome Market: https://www.delveinsight.com/report-store/acute-radiation-syndrome-pipeline-insight
• Human Papillomavirus Hpv Market: https://www.delveinsight.com/report-store/human-papillomavirus-hpv-market
• Blood Gas And Electrolyte Analyzers Market: https://www.delveinsight.com/report-store/blood-gas-and-electrolyte-analyzers-market
Contact Us:
Gaurav Bora
gbora@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Endometriosis Pipeline 2024: Detailed Clinical Trials and FDA-Approved Therapies Review by DelveInsight | Organon, Ironwood Pharma, AbbVie/Neurocrine Biosciences, Mitsubishi Tanabe Pharma Corporation here
News-ID: 3818921 • Views: …
More Releases from DelveInsight Business Research
Short Bowel Syndrome Market on Track for Major Expansion by 2034, According to D …
DelveInsight's "Short Bowel Syndrome Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Short Bowel Syndrome, historical and forecasted epidemiology as well as the Short Bowel Syndrome market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Short Bowel Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Short Bowel Syndrome…
Gastroparesis Market Forecasted to Surge in Coming Years, 2024-2034 Analysis by …
DelveInsight's "Gastroparesis Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Gastroparesis, historical and forecasted epidemiology as well as the Gastroparesis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Gastroparesis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Gastroparesis Market Forecast
https://www.delveinsight.com/sample-request/gastroparesis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the key facts of the Gastroparesis…
Uveitis Pipeline 2025: Therapies, MOA Insights, and Key Clinical Trial Updates b …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Uveitis pipeline constitutes 15+ key companies continuously working towards developing 15+ Uveitis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Uveitis Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Uveitis Market.
The Uveitis Pipeline report embraces in-depth…
Aplastic Anemia Market Expected to Experience Major Growth by 2034, According to …
DelveInsight's "Aplastic Anemia Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Aplastic Anemia, historical and forecasted epidemiology as well as the Aplastic Anemia market trends in the United States, EU4 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
To Know in detail about the Aplastic Anemia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Aplastic Anemia Market Forecast
https://www.delveinsight.com/report-store/aplastic-anemia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the…
More Releases for Endometriosis
Endometriosis Treatment Market at $1.55B, 7.7% CAGR
Why Is the Global Endometriosis Treatment Market Expanding So Quickly?
The endometriosis treatment market has grown rapidly in recent years, primarily due to increased awareness, better diagnostic technologies, rising cases of reproductive health disorders, and significant investment in research and drug development. With the market valued at USD 1.55 billion in 2024 and expected to reach USD 3.25 billion by 2034, the global demand for effective treatments continues to accelerate.
Endometriosis affects…
Endometriosis Pain Market Massive Growth opportunity Ahead
Introduction
Endometriosis is a chronic, estrogen-dependent condition in which endometrial-like tissue grows outside the uterus, leading to inflammation, scarring, and adhesions. One of its most debilitating symptoms is pelvic pain, often accompanied by painful periods, infertility, and fatigue. Globally, endometriosis affects an estimated 10% of women of reproductive age, making it a major public health concern.
Despite its prevalence, endometriosis pain has historically been underdiagnosed and undertreated. Patients often face diagnostic delays…
Elevated Ovarian Cancer Incidence Fuels Growth In The Endometriosis Market: A Ke …
The Endometriosis Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Current Endometriosis Market Size and Its Estimated Growth Rate?
In recent years, there has been a swift expansion in the market size of endometriosis. This market is projected to increase from $1.4 billion…
Hope for Rapid, Non-Invasive Endometriosis Diagnosis
New diagnostic test for endometriosis, the ENDOSURE test, offers decision support to clinicians with 99.87% accurate results in less than an hour, could transform women's healthcare
EDMONTON, AB - In a groundbreaking development for women's health featured on Global News Calgary by journalist Jayme Doll on March 12, 2025, the ENDOSURE test emerges as a beacon of hope for millions suffering from undiagnosed endometriosis in. This non-invasive diagnostic tool promises to…
Emerging Endometriosis Market Trend 2025-2034: Innovative Medications Reshaping …
"How Is the Endometriosis Market Projected to Grow, and What Is Its Market Size?
The endometriosis market has seen rapid growth in recent years. It is expected to grow from $1.4 billion in 2024 to $1.55 billion in 2025, at a compound annual growth rate (CAGR) of 10.2%. The growth can be attributed to delayed diagnosis, increased awareness, advances in laparoscopic surgery, hormonal therapies, and the support of patient advocacy groups.
The…
Endometriosis Treatment Market Analysis, Size, Share & Trends | 2031
In recent years, the global Endometriosis Treatment Market has witnessed a dynamic shift, influenced by changing consumer preferences, technological advancements, and a growing emphasis on sustainability. The Research report on Endometriosis Treatment Market presents a complete judgment of the market through strategic insights on future trends, growth factors, supplier landscape, demand landscape, Y-o-Y growth rate, CAGR, pricing analysis. It also provides and a lot of business matrices including Porters Five…
